Competitor Analysis: TGF-beta/Receptor Inhibitors

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 59
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0178
Release Date: September of 2019

Competitor Analysis: TGF-beta/Receptor Inhibitors

This Competitive Intelligence report about TGF-beta/Receptor Inhibitors evaluates the landscape of investigational new molecular entities targeting transforming growth factor beta (TGF-β) and TGF-β receptor kinase for treatment of cancer or fibrosis as of September 2019.

Several cytokines and growth factors are involved in the tight regulation of either antitumor immunity or immunosuppressive tumor-promoting inflammation within the tumor microenvironment (TME), of which transforming growth factor beta (TGF-β) is of particular importance. In mammals three TGF-β isoforms are described (TGF-β1, 2, and 3) which are the primary mediators of TGF-β cell transduction. All isoforms are synthesised as propeptides that form dimers which require maturation before being able to bind to their receptors. These dimers are composed of the C-terminal TGF-β ligand as well as an N-terminal latency-associated propeptide (LAP), with which the complex gets sequester to proteins of the extracellular matrix (ECM).

As preclinical studies implicate the use of TGF-β inhibition as a potential therapeutic target, monoclonal antibodies against all three isoforms of TGF-β, as well as TGF-βR inhibitors, are currently tested in various solid cancers. As the response to anti-PD-1 monotherapy appears to be mainly limited by the number of preexisting cytotoxic T cells, concurrent TGF-β inhibition provides a powerful strategy to (a) improve T cell priming within the lymph nodes, (b) enhance cytotoxic destruction of tumor cells, and (c) reduce the appearance of immune suppressive immune cells.

The report includes a compilation of currently active projects in research and development of TGF-β/R inhibitors for treatment of fibrosis and cancer, respectively. In addition, the report lists company-specific R&D pipelines of TGF-β and TGF-β receptor kinase inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Table of Contents

1)        Cancer Indications

Indirect TGF-β Inhibition

Selective TGF-β1 Inhibition

Selective TGF-β2 Inhibition

Dual and Pan-TGF-β Inhibition

Bispecific TGF-β Inhibition

Cell Therapeutics with TGF-β Inhibition

2)        Non-Cancer Indications with TGF-β Inhibition

3)        Corporate RORgamma Antagonist & Agonist R&D Pipelines

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01